Archive for the ‘BMS’ Category
Posted by kinasepro on March 26, 2009
The N-Oxide is a major metabolite, and from the trial notes its either toxic, potent, or prevalent… The J Med Chem doesn’t mention it.
Posted by kinasepro on August 21, 2007
Posted by kinasepro on May 1, 2007
Posted by kinasepro on April 10, 2007
BMS-582664 / Brivanib alaninate
WO/2007/038648 is a development ‘crystalline forms’ application from BMS.
Posted by kinasepro on April 8, 2007
Sprycel ®, dasatinib, BMS-354825
Discovery: Bristol-Myers Squibb WO/2000/062778
US Approval: June 2006
Named after its inventor?
Posted by kinasepro on January 6, 2007
So if your on the Aurora program at BMS you had to be a little disturbed when you saw US2006084650 with a priority date of: Oct 15, ’04 come out back in April ’06 as your earliest provisionals are from July 1 ’05. Who knows maybe there’s enough room in the sandbox for both. Takeda’s primary series appears to be the imidazopyrimidine anyways, but the pyrollo compounds are claimed and exemplified.
Posted by kinasepro on December 21, 2006
but this is the first I’ve heard of the morpholine.
Posted by kinasepro on December 19, 2006
While not saying what for I think its safe to assume they’ll hit a kinase or two along the way.
…upfront payment of $60 million in cash. Exelixis will also receive $20 million for each of up to three different drug candidates selected by Bristol-Myers Squibb at IND…
Sweetheart oncology deal. boring webcast here.
>> update: 8k, The check must-a-been postdated.